RMD — RESMED INC
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 943819 ·
Last close
$226.00
Market Cap
$32.78B
52W High
$226.61
52W Low
$180.27
ADV30
1,502,581
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 1,431,406,000 | 890,979,000 | 499,810,000 | 398,732,000 | 8,784,285,000 | 1,660,513,000 | 2,292,374,000 |
| Dec 2025 | 1,422,808,000 | 878,724,000 | 497,595,000 | 392,593,000 | 8,503,370,000 | 1,417,069,000 | 2,182,491,000 |
| Sep 2025 | 1,335,582,000 | 820,820,000 | 462,347,000 | 348,536,000 | 8,308,352,000 | 1,383,848,000 | 2,187,088,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,889,964,000
Investing CF
$-295,261,000
Financing CF
$-907,752,000
CapEx
$-153,701,000
Dividends Paid
$-340,162,000
Buybacks
$-600,045,000
EPS Diluted TTM
$10.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$6,958,779,000
Inventory
$911,876,000
Receivables
$1,045,943,000
ST Investments
—
EBIT TTM
$1,916,323,000
Pretax Income TTM
$1,903,306,000
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,653,443,072
EBITDA
$2,121,287,936
Free Cash Flow
$939,248,256
Enterprise Value
$32,060,241,920
Total Cash
$1,469,234,048
Total Debt
$825,918,976
Shares Out
145,056,384
Trailing EPS
$10.49
Book Value
$45.51
ROE
24.3%
ROA
14.0%
Div Yield
1.17%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 5,146,327,000 | 1,687,394,000 | 1,400,723,000 | 8,174,391,000 | 2,206,532,000 | — | 1,751,588,000 |
| Jun 2024 | 4,685,297,000 | 1,384,121,000 | 1,020,951,000 | 6,872,394,000 | 2,008,351,000 | — | 1,401,260,000 |
| Jun 2023 | 4,222,993,000 | 1,151,997,000 | 897,556,000 | 6,751,708,000 | 2,621,805,000 | — | 693,299,000 |
| Jun 2022 | 3,578,127,000 | 1,002,150,000 | 779,437,000 | 5,095,853,000 | 1,735,102,000 | — | 351,147,000 |
TTM Snapshot
Revenues TTM
$4,958,138,000
NetIncome TTM
$1,290,228,000
OpCashFlow TTM
$0
Assets (Latest)
$8,174,391,000
Forward EPS
$13.24
Max Pain — expiry 2026-08-21
max pain strike: $210.00 · spot: $226.74 · call oi: 6,344 · put oi: 4,230
Expected Move to 2026-08-21:
±$7.92
(3.50%) —
implied range
$218.82 –
$234.67
· ATM straddle on $230.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc. | $32.88B | $72.28 | — |
| DXCM | DEXCOM INC | $34.26B | $90.80 | — |
| MDLN | Medline Inc. | $31.15B | $35.50 | — |
| FSNUY | Fresenius SE & Co. KGaA | $30.73B | $13.64 | — |
| FSNUF | Fresenius SE & Co. KGaA | $30.61B | $54.35 | — |
News headlines (Yahoo Finance, 1h cache)
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?
2026-08-12 02:33 · Yahoo
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
2026-08-10 05:33 · Yahoo
ResMed Q4 Earnings Call Highlights
2026-08-09 04:03 · Yahoo
ResMed Shares Fall After Revenue Miss and Conservative 2027 Outlook
2026-08-07 12:41 · Yahoo
ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
2026-08-07 05:12 · Yahoo
ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
2026-08-06 21:47 · Yahoo
ResMed (RMD) Faces An Earnings Test After A Rebound That Still Looks Undervalued
2026-08-06 13:16 · Yahoo
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook
2026-08-12 10:12 · Yahoo
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
2026-08-11 16:23 · Yahoo
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
2026-08-11 16:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.